Introduction
============

Breast cancer is one of the most common cancers affecting the morbidity and mortality of females worldwide ([@b1-etm-05-05-1397]). While numerous risk factors for breast cancer have been identified, including genetic predisposition and estrogen level, the molecular mechanisms related to breast carcinogenesis remain under analysis ([@b2-etm-05-05-1397],[@b3-etm-05-05-1397]). Previous studies have shown alterations in cell cycle regulatory proteins in breast carcinoma, including the overexpression and increase of the cyclin genes, inactivation and deletions of the Rb gene and alterations of the p53 gene ([@b4-etm-05-05-1397]--[@b6-etm-05-05-1397]). Therefore, this disease is a result of collective alterations of oncogenes and tumor suppressor genes. It is well-known that p53, the guardian of the genome, is a stress response protein. p53 functions mainly as a tetramer transcription factor that regulates a large number of genes in response to various stresses, including ontogeny activation and DNA damage ([@b7-etm-05-05-1397]). p53 is involved in the pro-survival response of cell cycle arrest and DNA damage repair, as well as the pro-death response of apoptosis ([@b8-etm-05-05-1397]). In the case of a mutation occurring in the p53 gene, p53 may not only lose its normal functions, but also gain new abilities that promote tumorigenesis ([@b9-etm-05-05-1397]). p53 is the most frequently mutated gene in human tumors; \>50% of tumors harbor mutations in the p53 gene ([@b10-etm-05-05-1397]). Besides its role as a tumor suppressor gene, aberrant p53 expression may play a significant role in regulating angiogenesis ([@b11-etm-05-05-1397],[@b12-etm-05-05-1397]). Chromosomal aberrations and p53 protein abnormalities may be involved in malignant transformation of endometriosis in the ovary ([@b13-etm-05-05-1397]).

The p53 tumor suppressor gene contains 11 exons, located on chromosome 17p13. The codon 72 polymorphism (rs1042522) is located in exon 4 with a CGC to CCC transition, leading to an arginine to proline amino acid substitution in amino acid position 72 (Arg72Pro). Studies have reported that the codon 72 polymorphism is associated with a risk for the development of cancer ([@b14-etm-05-05-1397]). The two polymorphic variants have been shown to have not only structural differences, as reflected by distinct electrophoresis patterns of migration, but also different biological properties ([@b15-etm-05-05-1397],[@b16-etm-05-05-1397]). A number of case-control studies have been conducted to explore the correlation between the p53 codon 72 polymorphism and breast cancer risk in humans. However, the results are inconsistent. Another problem is that these published studies have only modest sample sizes, which limits their significance. By performing a meta-analysis, a prevailing method for the quantitative summary of different results, the data may be assessed and the sample size increased to a reasonable level. In the present study, a meta-analysis was conducted to quantitatively assess the effect of the p53 codon 72 polymorphism on the risk of breast cancer.

Materials and methods
=====================

Publication search
------------------

PubMed was searched using the terms 'p53', 'polymorphism' and 'breast cancer' (the last search update was on May 1, 2012). The search was limited to English-language papers. Additional studies were identified by a manual search of the references of original studies. Of the studies with the same or overlapping data published by the same investigators, the most recent ones with the largest number of subjects were selected. Case-control studies containing available genotype frequencies of Arg72Pro were selected.

Statistical analysis
--------------------

For the control group of each study, the allelic occurrence was considered and the observed genotype frequencies of the p53 codon 72 polymorphism were assessed for Hardy-Weinberg equilibrium using the *χ*^2^ test. The power of the correlation between the p53 codon 72 polymorphism and breast cancer risk was assessed by odds ratios (ORs) with 95% confidence intervals (CIs). The risks of breast cancer for the GC and CC genotypes, relative to the wild-type GG homozygote were assessed; then, the risks of breast cancer for GC/CC vs. GG and CC vs. GC/GG, and finally the supercilious dominant and recessive effects of the variant C allele were determined. Stratified analyses according to background, the source of controls and clinicopathological individuality were also performed. In considering the possibility of heterogeneity across the studies, an arithmetical test for heterogeneity was performed based on the Q-test. P\<0.05 for the Q-test was considered to indicate a lack of heterogeneity among the studies. The summary OR estimate of each study was calculated by the random effects model ([@b17-etm-05-05-1397],[@b18-etm-05-05-1397]). The potential for publication bias was examined by Begg's test and Egger's linear regression test. P\<0.05 was considered to indicate a statistically significant difference ([@b19-etm-05-05-1397]). All statistical analyses were performed with Stata software (version 9.0; Stata Corporation, College Station, TX, USA).

Results
=======

Sixty-one case-control studies concerning the association between p53 codon 72 polymorphism and breast cancer were identified, which included 28,539 breast cancer cases and 32,788 controls. These data were used in a meta-analysis ([Table I](#t1-etm-05-05-1397){ref-type="table"}). The sharing of genotypes in the controls of all the studies was in agreement with Hardy-Weinberg equilibrium.

The results of the association between the p53 codon 72 polymorphism and breast cancer and the heterogeneity test are shown in [Table II](#t2-etm-05-05-1397){ref-type="table"}. The dominant model (Pro/Pro + Pro/Arg vs.Arg/Arg) demonstrated no significant association in Asian (OR=1.028, 95% CI=0.879--1.201, P=0.732), Caucasian (OR=1.036, 95% CI=0.927--1.159, P=0.531) or other subjects (OR=1.016, 95% CI=0.931--1.11, P=0.722).

Discussion
==========

Given the important roles of p53 in multiple cellular functions, including gene transcription, DNA repair and apoptosis, it is biologically plausible that p53 polymorphisms may be associated with a risk of breast cancer ([@b20-etm-05-05-1397]). Human breast cancer is a disease with significant clinical consequences. The mechanism of breast cancer remains relatively unknown. Single nucleotide polymorphisms (SNPs) are used as a tool to investigate genetic variations and disease susceptibility.

Although a number of previous studies have reported a significant association between the p53 codon 72 polymorphism and breast cancer risk ([@b21-etm-05-05-1397]--[@b34-etm-05-05-1397]), others have identified no such association ([@b35-etm-05-05-1397]--[@b39-etm-05-05-1397]). In order to resolve this conflict, in the current study, a meta-analysis was conducted to examine the association between a commonly studied p53 polymorphism (codon 72 G\<C, Arg72Pro) and breast cancer risk. A total of 28,539 breast cancer cases and 32,788 controls from 61 studies were included in the final analysis, to derive a more precise estimation of the presence or absence of this association. The polymorphism in codon 72 of the p53 gene was identified to have no association with breast cancer risk, either when the incorporated study populations were pooled or when they were subjected to a stratified analysis consistent with background or the source of controls. The latter result suggests that differences in genetic education, living environment and sources of controls do not impact any potential association between the p53 codon 72 polymorphism and breast cancer risk. Two assets of the current study were the large number of samples included and its failure to identify a significant association in any of the genetic models tested. Nevertheless, several limitations must be acknowledged. The controls in the studies were not homogenously defined, such that the control subjects in the different studies have varying risks of evolving breast cancer. Additionally, the results obtained in the present study are based on unadjusted estimations. A more accurate analysis could be conducted if more detailed individual data were available to allow it to be adjusted according to other covariates, including premenopause, postmenopause, smoking and drinking status, basal metabolic index, family history and environmental factors.

In conclusion, this meta-analysis, with a large model size, provides a strong indication that the p53 codon 72 polymorphism is not associated with breast cancer risk. Future studies should extend this investigation by incorporating other potential risk factors for breast cancer.
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###### 

Distribution of the p53 codon 72 polymorphism for cases and controls.

                                                             Breast cancer   Control                              
  ----------- --------------------------------------- ------ --------------- --------- ------ ----- ------ ------ ------
  Asian       Kawajiri ([@b40-etm-05-05-1397])        1993   5               51        37     38    165    144    0.36
              Khaliq ([@b41-etm-05-05-1397])          2000   13              18        10     177   321    191    0.08
              Li ([@b30-etm-05-05-1397])              2002   6               11        11     14    26     10     0.74
              Huang ([@b28-etm-05-05-1397])           2003   36              100       64     30    138    114    0.21
              Katiyar ([@b29-etm-05-05-1397])         2003   6               51        20     8     24     9      0.27
              Mahasneh ([@b42-etm-05-05-1397])        2004   8               19        16     29    51     56     0.01
              Noma ([@b43-etm-05-05-1397])            2004   29              69        93     31    76     111    0.00
              Siddique ([@b44-etm-05-05-1397])        2005   20              38        36     38    120    107    0.64
              Ma ([@b45-etm-05-05-1397])              2006   77              178       149    100   222    150    0.29
              Gochhait ([@b26-etm-05-05-1397])        2007   48              109       86     97    160    76     0.52
              Khadang ([@b37-etm-05-05-1397])         2007   29              109       83     40    90     75     0.17
              Rajkumar ([@b46-etm-05-05-1397])        2008   59              125       66     141   224    135    0.02
              Zhang ([@b34-etm-05-05-1397])           2007   17              45        21     33    87     47     0.52
              Lum ([@b47-etm-05-05-1397])             2008   88              200       105    13    38     29     0.93
              Singh ([@b48-etm-05-05-1397])           2008   13              45        46     12    64     29     0.01
              Kazemi ([@b49-etm-05-05-1397])          2009   6               30        6      0     45     12     0.00
              Song ([@b50-etm-05-05-1397])            2009   221             544       339    220   508    349    0.16
              Koh ([@b51-etm-05-05-1397])             2011   102             197       73     179   319    145    0.90
              Kara ([@b52-etm-05-05-1397])            2010   105             84        14     72    80     17     0.44
              Leu ([@b53-etm-05-05-1397])             2011   71              90        78     104   129    88     0.00
  Caucasian   Själander ([@b22-etm-05-05-1397])       1996   24              93        95     61    253    375    0.06
              Weston ([@b33-etm-05-05-1397])          1997   6               27        32     3     42     72     0.28
              Wang-Gohrke ([@b54-etm-05-05-1397])     1998   5               46        56     21    117    167    0.93
              Papadakis ([@b55-etm-05-05-1397])       2000   12              10        34     6     41     12     0.00
              Wang-Gohrke ([@b32-etm-05-05-1397])     2002   49              221       282    40    203    300    0.49
              Buyru ([@b25-etm-05-05-1397])           2003   12              39        64     12    43     21     0.20
              Suspitsin ([@b56-etm-05-05-1397])       2003   42              203       284    27    159    207    0.63
              Menzel ([@b57-etm-05-05-1397])          2004   30              170       275    30    114    158    0.17
              Kalemi ([@b23-etm-05-05-1397])          2005   3               13        26     9     32     10     0.07
              Ohayon ([@b58-etm-05-05-1397])          2005   3               40        89     19    94     54     0.02
              Tommiska ([@b39-etm-05-05-1397])        2005   109             617       825    52    278    403    0.67
              Baynes ([@b35-etm-05-05-1397])          2007   148             768       1107   166   854    1177   0.52
              Garcia-Closas ([@b59-etm-05-05-1397])   2007   196             1021      1368   228   1249   1774   0.69
              Franeková ([@b60-etm-05-05-1397])       2007   8               34        49     9     55     92     0.84
              Johnson ([@b61-etm-05-05-1397])         2007   30              185       257    183   925    1354   0.15
              Schmidt ([@b38-etm-05-05-1397])         2007   618             3228      4499   511   2677   3661   0.48
              Sprague ([@b31-etm-05-05-1397])         2007   100             644       909    129   704    1021   0.61
              Akkiprik ([@b24-etm-05-05-1397])        2009   20              50        25     12    49     46     0.85
              Cavallone ([@b62-etm-05-05-1397])       2008   10              67        80     9     46     57     0.95
              Costa ([@b63-etm-05-05-1397])           2008   25              86        137    54    212    380    0.00
              De Vecchi ([@b64-etm-05-05-1397])       2008   15              150       185    14    131    207    0.23
              Nordgard ([@b65-etm-05-05-1397])        2008   5               58        46     14    34     73     0.00
              Lång ([@b66-etm-05-05-1397])            2009   6               45        65     5     58     79     0.15
              Denisov ([@b77-etm-05-05-1397])         2009   25              124       148    29    99     147    0.05
              Henríquez ([@b27-etm-05-05-1397])       2009   8               54        73     28    100    167    0.03
              Hrstka ([@b68-etm-05-05-1397])          2009   40              15        62     45    8      55     0.00
              Bisof ([@b69-etm-05-05-1397])           2010   11              23        61     5     42     61     0.51
              Ebner ([@b70-etm-05-05-1397])           2010   17              108       138    14    103    137    0.34
              Kara ([@b52-etm-05-05-1397])            2010   14              84        105    17    80     72     0.44
              Alshatwi ([@b71-etm-05-05-1397])        2012   22              52        26     32    51     17     0.66
              Alawadi ([@b72-etm-05-05-1397])         2011   81              200       7      50    112    26     0.00
  Others      Weston ([@b33-etm-05-05-1397])          1997   1               9         6      4     14     12     0.98
              Weston ([@b73-etm-05-05-1397])          1994   7               8         3      12    16     10     0.34
              Helland ([@b74-etm-05-05-1397])         1998   6               40        63     13    90     122    0.50
              Mabrouk ([@b36-etm-05-05-1397])         2003   3               9         18     4     26     19     0.23
              Damin ([@b21-etm-05-05-1397])           2006   64              48        6      70    111    21     0.02
              Cox ([@b75-etm-05-05-1397])             2007   104             569       804    131   838    1255   0.57
              Gaudet ([@b76-etm-05-05-1397])          2008   46              244       288    34    138    218    0.08
              Aoki ([@b67-etm-05-05-1397])            2009   3               29        40     7     53     30     0.01

P-value for Hardy-Weinberg equilibrium in the control group.

###### 

ORs and 95% CI for breast cancer and the p53 codon 72 polymorphism under different genetic models.

  Genetic model                          Population             Pooled OR (95% CI)     P-value   P-value           
  -------------------------------------- ---------------------- ---------------------- --------- --------- ------- -------
  Additive (Pro vs. Arg)                 Asian                  1.016 (0.958--1.077)   0.539     \<0.001   0.948   0.889
  Caucasian                              1.002 (0.972--1.033)   0.903                  \<0.001   0.368     0.417   
  Others                                 0.956 (0.88--1.039)    0.288                  \<0.001   0.463     0.388   
  Overall                                1 (0.975--1.026)       0.993                  \<0.001   0.356     0.357   
  Recessive (Pro/Pro vs. Arg-carriers)   Asian                  1.012 (0.882--1.162)   0.861     0.01      0.846   0.862
  Caucasian                              1.019 (0.916--1.134)   0.726                  \<0.001   0.486     0.602   
  Others                                 1.168 (0.852--1.602)   0.335                  \<0.001   1         0.356   
  Overall                                1.029 (0.95--1.115)    0.479                  \<0.001   0.602     0.37    
  Dominant (Pro-carriers vs. Arg/Arg)    Asian                  1.028 (0.879--1.201)   0.732     0.012     0.506   0.921
  Caucasian                              1.036 (0.927--1.159)   0.531                  0.035     0.773     0.599   
  Others                                 0.912 (0.651--1.277)   0.591                  0.064     0.835     0.299   
  Overall                                1.016 (0.931--1.11)    0.722                  0.001     0.565     0.36    
  Pro/Arg vs. Arg/Arg                    Asian                  1.027 (0.887--1.188)   0.725     0.082     0.916   0.931
  Caucasian                              1.045 (0.926--1.179)   0.473                  0.028     0.959     0.868   
  Others                                 0.884 (0.652--1.199)   0.428                  0.16      0.835     0.567   
  Overall                                1.018 (0.933--1.111)   0.689                  0.007     0.904     0.739   
  Pro/Pro vs. Arg/Arg                    Asian                  1.035 (0.843--1.272)   0.74      0.001     0.248   0.829
  Caucasian                              1.029 (0.881--1.203)   0.717                  \<0.001   0.444     0.667   
  Others                                 1.021 (0.673--1.55)    0.922                  0.042     0.345     0.377   
  Overall                                1.028 (0.916--1.153)   0.639                  \<0.001   0.188     0.385   

OR, odds ratio; CI, confidence interval.
